Ergoteles’s TherapeuticsMD TXMD Stock Holding History

Ergoteles’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-84,700	Closed	-$843K	–	1997
2022 Q2	$843K	Buy	+84,700	New	+$809K	0.03%	616

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

Ergoteles's TXMD Position: Q3 2022 in Review

Ergoteles sold out of TherapeuticsMD (TXMD) in Q3 2022, closing a stake of 84,700 shares — an estimated $843K sold.

Ergoteles first reported a position in TXMD in Q2 2022 and held it in 1 quarter. The position peaked at $843K in Q2 2022. 43 funds tracked by Wall St. Rank hold TXMD as of Q3 2022.

Ergoteles reported no remaining TherapeuticsMD position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 84,700 TherapeuticsMD shares in Q3 2022, an estimated $843K.
Ergoteles first reported a position in TherapeuticsMD in Q2 2022 and held it in 1 quarter.
Ergoteles's TherapeuticsMD position peaked at $843K in Q2 2022.
43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.